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Summary 
Continuous administration of soluble proteins, delivered over a 10-d period by a mini-osmotic 
pump  implanted subcutaneously, induces a long-lasting inhibition of antigen-specific T  cell 
prohferation in lymph node cells from BALB/c mice subsequently primed with antigen in ad- 
juvant. The decreased T  cell proliferative response is associated with a down-regulation of the 
T  helper cell (Th)l cytokines interleukin (IL)-2 and interferon (IFN)-~/and with a strong in- 
crease  in the secretion of the Th2 cytokines IL-4 and IL-5 by antigen-specific CD4 + T  cells. 
This  is  accompanied by predominant  inhibition  of antigen-specific antibody production of 
IgG2a and IgG2b, rather than IgG1  isotype. Interestingly, inhibition of Thl  and priming of 
Th2 cells is also induced in 132-microglobuhn-deficient BALB/c mice, indicating that neither 
CD8 + nor CD4 § NKI.1 + T  cells, respectively, are required. The polarization in Th2 cells is 
stably maintained by T cell hnes, all composed ofCD4+/CD8 -  cells expressing T  cell receptor 
for antigen (TCR.)c~/I3 chains, derived from BALB/c mice treated with continuous antigen ad- 
ministration, indicating that they originate from Th2 cells fully differentiated in vivo. This po- 
larization is  induced in BALB/c mice by continuous administration  of any protein  antigen 
tested, including soluble extracts from pathogenic microorganisms. Priming of Th2 cells is dose 
dependent and it is optimal for low rather than high doses of protein. Blocking endogenous 
IL-4 in vivo inhibits expansion of antigen-specific Th2 cells, but does not restore IFN-~/pro- 
duction by T  cells from mice treated with soluble antigen, indicating the involvement of two 
independent mechanisms.  Consistent with this, Th2 cell development, but not inhibition of 
Thl cells, depends on non-major histocompatibility complex genetic predisposition, since the 
Th2 response is amphfied in BALB/c as compared to DBA/2, C3H, or C57BL/6 mice whereas 
inhibition of the Thl response is induced by soluble protein administration in any mouse strain 
tested. These findings support the hypothesis that continuous release of  low amounts of protein 
antigens from pathogenic microorganisms may polarize the immune response toward a Th2 
phenotype in susceptible mouse strains. 
D 
ifferential lymphokine production allows the subdivi- 
sion of  mouse (1), rat (2) and human (3) CD4 + T cells 
into three major subsets: T helper I  (Thl), characterized by 
secretion of IL-2  and  IFN-~;  Th2,  selectively producing 
IL-4 and IL-5; and Th0, which are not restricted in their 
lymphokine  production.  The  development  of Thl  and 
Th2  cells  is  primarily influenced by the  cytokine milieu 
during the initial phase of the immune response, in which 
IL-12 and IL-4, respectively, play decisive roles (4, 5). 
The functional significance of CD4 + T  cell subsets  has 
been first clearly demonstrated in vivo by studying the im- 
mune  response to infectious agents (1). In these situations, 
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development of the  appropriate  Th  subset  is  particularly 
important since certain pathogens are most effectively con- 
trolled by either a cellular (Thl-type) or a humoral (Th2- 
type) immune response (1, 6-8). The ability of pathogens 
to stimulate preferentially either Thl or Th2 responses de- 
pends  on several factors including genetic background of 
the host, type of infecting organism, stage  of infection and 
microbial load.  High  and low microbial loads  have been 
shown  to  induce  preferentially a  Th2-  or Thl-type  im- 
mune  response,  respectively, which  can be  protective or 
deleterious depending on the pathogen  (8,  9).  Therefore, 
dominance of an inappropriate T  cell response can exacer- 
bate the disease, leading to the inability to eradicate the in- 
vading  microorganism.  For example,  Th2  responses pre- 
dominate in overwhelming infections such as lepromatous 
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Volume 183  February 1996 485-497 leprosy (10),  leishmaniasis (6),  and helmintiasis (7).  In the 
latter model, egg-stimulated Th2  cells have been shown to 
down-regulate Thl  responses and it has been hypothesized 
that  the  physical properties  of eggs,  whose  protein  shell 
continuously releases antigen, could influence T  cell devel- 
opment (7,  11). 
To  analyze whether the continuous release of low dose 
protein antigen could selectively activate Th2  cells, which 
may represent the initial mechanism skewing the immune 
response against pathogens toward a nonprotective immu- 
nity,  we  have  used  mini-osmotic pumps  to  continuously 
deliver protein antigens to BALB/c mice. After continuous 
administration of soluble antigen, mice were primed with 
protein antigens in adjuvant and T  cell responses analyzed. 
In the present paper, we show that continuous administra- 
tion to BALB/c mice of any soluble protein antigen tested 
induces a long-lasting, antigen-specific unresponsiveness of 
CD4 §  Thl  cells  and  a  vigorous  priming  of CD4 +  Th2 
cells. Interestingly, continuous administration of low rather 
than high  doses of antigen by mini-osmotic pumps  is the 
most efficient in inducing Th2 cells. Crude soluble protein 
extracts from pathogens such as Mycobacterium  tuberculosis  or 
soluble leishmania antigen are also very effective in selec- 
tively inducing antigen-specific Th2  cells when  delivered 
by  mini-osmotic  pumps  to  BALB/c  mice.  These  results 
suggest that continuous release of soluble proteins by infec- 
tious microorganisms represents a  critical stimulus for Th2 
cell induction in susceptible mouse strains. 
Materials and Methods 
Mice.  2- to 3-too-old BALB/c, DBA/2, C3H, and C57BL/6 
female  mice  were  purchased  from  Charles  P,  dver  Laboratories 
(Calco,  Italy). H-2  b mice with disrupted IB2M genes  (12)  were 
back-crossed to BALB/c mice to obtain H-2 a ]B2M  -/- mice (13). 
Expression of H-2  a was  determined by cell surface  staining for 
class II molecules and by Southern blot hybridization. 132M  -/- 
mice were identified by lack of  MHC class I expression as assessed 
by cell surface  staining using FITC-SFI-I.1 (anti-Kd;  PharMin- 
gen, San Diego, CA) mAb (14). IB2M  -/- mice on BALB/c back- 
ground were used after seven back-crosses. H-2  a I~2M  -/  mice, 
at the fourth back-cross, were a kind gift of Dr.  Faith B. Wells 
and Louis A. Marls (NCI, Frederick, MD). 
Antigens.  Hen  egg-white lysozyme (HEL), 1 bovine RNase, 
OVA, human hemoglobin, and human transferrin were obtained 
from Sigma Chemical Co. (St. Louis, MO). Recombinant 65-kD 
heat shock protein (hsp)  of M.  tuberculosis was a kind gift of Dr. 
Ruurd van der Zee (National Institute of Public Health and En- 
vironmental  Protection,  Bilthoven,  The  Netherlands).  Tuber- 
culin  purified  protein  derivate  (PPD)  (Statens  Seruminstitut, 
Copenhagen, Denmark) was sequentially centrifuged for 10 rain 
at 15,000  g and then for 1 h  at 100,000  g to remove aggregates 
and insoluble material. A soluble extract from 1.5 ￿  108 Leishma- 
nia major promastigotes was prepared following a standard freeze- 
thaw  procedure  and  kindly provided by  Dr.  G.  Alber  (Hoff- 
mann-La Roche, Basel,  Switzerland). All protein antigens were 
1Abbreviations used in this paper: HEL, hen egg-white lysozyme; hsp, heat 
shock protein; LNC, lymph node cells; PPD, tubercuhn purified protein 
derivative; TCL, T cell line. 
filtered  on  0.22-p.m  membranes  before  use.  Peptides  were 
synthesized by the solid-phase method on phenylacetamidome- 
thyl-polystyrene support  using  side-chain protection,  coupling 
procedures and  an  automated apparatus  (model 430A;  Applied 
Biosystems, Inc., Foster City, CA). Crude peptides were purified 
by preparative HPLC  on C18  reverse-phase column.  The  pep- 
tides showed correct amino acid ratios upon hydrolysis in  6  N 
HC1 and the expected molecular ions in fast atom bombardment 
mass spectrometry. Sequences were confirmed by gas-phase mi- 
crosequencing. 
Delivery by Mini-Osmotic Pumps,  Immunizations,  and Anti-IL-4 
Treatment.  Mini-osmotic pumps  (Alzet 2001;  Alza Corp., Palo 
Alto,  CA)  were  implanted subcutaneously  in  the  dorsal  flank 
through a 5-ram-long cut in the skin of the lumbar region and 
the wound was closed by metal stitches.  The mean fiH volume of 
pumps was ,'~  Ixl and the mean pumping rate ~1  txl/h, deliv- 
ering  continuously for  ~10  d.  12  d  after pump  implantation, 
mice  were  immunized  subcutaneously  into  the  hind  footpads 
with the indicated amount of antigen emulsified in IFA or CFA 
containing H37Ra  mycobacteria (Difco Laboratories, Inc., De- 
troit, MI). 
For anti-IL-4 mAb treatment, mice were injected i.p. with  1 
mg/mouse of protein G-purified 11B11 mAb (HB188; American 
Type Culture Collection, Rockville, MD) in PBS at the day of 
pump implantation, and then with 0.5 mg/mouse 4 and 8 d later. 
Control  mice  were  injected with  the  same  amount  of isotype 
control LO-DNP-2 rat mAb, or with PBS only. LO-DNP-2 is a 
TNP-specific rat  IgG1  mAb kindly provided by Dr.  H.  Bazin 
(University of Louvain, Brussels, Belgium). 
T  Cell Assays.  For T  cell proliferation assays, popliteal lymph 
nodes were removed, and 4 X 105 cells/well were cultured in 96- 
well culture plates (Costar Corp., Cambridge, MA) in synthetic 
HL-1  medium  (Ventrex  Laboratories,  Portland,  ME)  supple- 
mented  with  2  mM  L-glutamine  and  50  Ixg/ml  gentamicin 
(Sigma) with the indicated antigen concentrations. Cultures were 
incubated for 3 d in a humidified atmosphere of 5% CO2 in air 
and were pulsed 8 h before harvesting with 1 txCi [3H]TdR (40 
Ci/nmol;  Radiochemical Centre,  Amersham,  UK).  Incorpora- 
tion of [3H]TdR was measured by liquid scintillation spectrome- 
try. For cytokine production analysis, LN cells (LNC) were cul- 
tured at 6 X  10  s cells/well as indicated above. Supernatants from 
replicate cultures, usually four to six wells, were collected after 
20-72  h  and pooled for cytokine analysis.  For blocking experi- 
ments,  cultures were performed in the presence of 5  btg/ml of 
GK1.5 anti-CD4 (TIB 207; American Type Culture Collection), 
or KT1.5  anti-CD8  (15)  mAb. These mAb were purified from 
culture  supernatant  by  affinity chromatography  on  a  protein 
G-Sepharose column. 
Cytokine Assays.  For IL-2 determination, supernatants were 
harvested after 20  h  of culture.  IL-2  concentration was  deter- 
mined using the IL-2-dependent CTL line proliferation assay and 
mouse rIL-2 (PharMingen)  to generate standard curves. Results 
were expressed as picograms per milliliter mouse rIL-2. IFN-~, 
IL-4, and IL-5 were quantified by two-sites sandwich ELISA. For 
IFN-'/, polyvinyl microtiter plates (3012;  Falcon Labware, Ox- 
nard, CA) were coated with 100 txl of AN-18.17.24 mAb (16) in 
carbonate buffer. After blocking, samples (50 Ixl/well) diluted in 
test solution (PBS containing 5% FCS and 1 g/liter phenol) were 
incubated together with  50  pd peroxidase-conjugated XMG1.2 
mAb (17).  After overnight incubation at 4~  bound peroxidase 
was detected by 3,3'-5, 5'-tetramethylbenzidine (Fluka Chemical 
Corp., Ronkonkoma, NY), and adsorbance read at 450 nm with 
an  automated  microplate  ELISA  reader  (MR5000;  Dynatech 
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tion two-sites ELISA was performed with paired mAb all pur- 
chased  from  PharMingen.  For capture,  the  mAb were  BVD4- 
1Dll  or  11Bll  (anti-IL-4),  and*TRFK5  (anti-IL-5).  Samples 
were titrated in test solution and incubated overnight at 4~  To 
detect bound cytokines, plates were then incubated with the bi- 
otinylated mAb BVD6-24G2  (anti-IL-4) or TR.FK4 (anti-IL-5) 
in PBS containing 0.1% Tween 20 and 1% BSA (PBSA-Tw). Af- 
ter washing, the bound biotinylated antibodies were revealed by 
an additional 30-rain incubation with alkaline phosphatase-con- 
jugated  streptavidin  (Jackson  Immunoresearch  Laboratories, 
Avondale, PA)  diluted  1:10,000.  The plates were  washed  again 
and incubated with the developing substrate p-nitrophenylphos- 
phate disodium (Sigma)  in diethanolamine buffer, pH 9.6,  (100 
pA/well). The reaction was stopped by adding 50 ixl/well NaOH 
3 N  and absorbance was read at 405 nm. Cytokines were quanti- 
fied from two to three titration points using standard curves gen- 
erated by purified recombinant mouse cytokines and results ex- 
pressed as cytokine concentration in nanograms or picograms per 
milliliter. Detection limits were  15 pg/ml for IFN-3' and IL-4, 3 
pg/ml for IL-5. 
In addition, IL-4 production was measured by using the IL-4-- 
dependent indicator cell line CTL44 (18).  Serial dilutions of cul- 
ture supernatants were incubated in 96-well plates (Costar) with 
5  5<  103 CTL44 cells/well for 48 h.  During the last 6 h  of cul- 
tures, the cells were pulsed with 1 p,  Ci [3H]TdR and thymidine 
incorporation measured as above. Standard curves were generated 
with  purified  recombinant mouse  IL-4  (PharMingen)  or  IL-4 
from H28 cell culture supernatant (a kind gift of Dr. E. Severin- 
son, University of Stockholm,  Stockholm,  Sweden).  The semi- 
tivity of this assay was <3 pg/ml. Similar amounts of IL-4 were 
revealed by ELISA and bioassay. 
Anti-HEL Antibody Determination.  HEL-coated polyvinyl micro- 
titer plates  (3012;  Falcon Labware)  were  incubated with serially 
diluted sera in PBSA-Tw for 90 rain at 37~  Plates were  then 
washed and incubated for 1 h at 37~  with a mixture (100 ng/ml 
each) of anti-IgM, -IgG1, -IgG2a, -IgG2b, -IgG3 biotin-conju- 
gated goat anti-mouse isotype-specific antibodies (Southern Bio- 
technology Associates Inc., Birmingham, AL). After washing, the 
bound anti-isotypic antibodies were revealed by an additional 1 h 
incubation  with  alkaline  phosphatase-conjugated  streptavidin 
(Jackson  Immunoresearch  Laboratories)  diluted  1:20,000.  The 
plates  were  washed  again,  incubated with  the  developing sub- 
strate  p-nitrophenylphosphate  disodium  (Sigma)  in  diethanola- 
mine buffer,  pH  9.6  (100  Ixl/well)  and absorbance read  at 405 
nm. Standard curves were generated using pooled anti-HEL sera 
and results expressed as arbitrary units per milliliter (U/ml; 1 U 
corresponding to 50% maximum OD). Anti-HEL IgG1, IgG2a, 
and lgG2b isotypes were determined as described above using the 
corresponding biotinylated isotype-specific antibodies.  Standard 
curves were obtained using calibrated serum pools revealed with 
anti-isotypic developing reagents,  and results expressed  as  units 
per milliliter. 
Flow Cytometry.  T  cell  lines  were  incubated  with  optimal 
concentrations of FITC- or biotin-conjugated  antibodies for 30 rain 
at 4~  in PBS containing 5% FCS, 0.1% sodium azide, and 1% 
normal rat serum to inhibit binding to FcR. The following mAbs 
(PharMingen)  were  used:  FITC-L3T4  (anti-CD4),  PE-53-6.7 
(anti-CD8a),  biotin-145-2C11  (anti-CD3-e),  and  biotin-H57- 
597  (anti-TCRo~/[]). Cells were  then washed and stained with 
PE-streptavidin  (Southern  Biotechnology).  Analysis  was  per- 
formed on a FACScan  |  flow cytometer (Becton Dickinson and 
Co., Mountain View, CA). Data were collected on 5,000-10,000 
viable cells as determined by forward light scatter intensity and 
propidium iodide exclusion, and analyzed using Lysis II software. 
Results 
Administration  of  Soluble  HEL  by  Mini-Osmotic  Pumps 
Readily  Inhibits  T  Cell Proliferation in LNC fiom Mice Subse- 
quently Primed with HEL-CFA.  BALB/c  mice  were  im- 
planted subcutaneously with mini-osmotic pumps deliver- 
ing continuously for ,~10  d  about 0.1  nmol/h  of HEL  or 
RNase.  12  d  after  pump  implantation mice  were  primed 
into the hind footpads with HEL emulsified in CFA, and 8 d 
later  antigen-specific  T  cell  proliferative  responses  were 
measured in draining popliteal lymph node cells. Results in 
Fig.  1 show that delivery of soluble HEL inhibits, although 
not completely, HEL-specific T  cell proliferation, whereas 
the response to PPD is unaffected. We also determined the 
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Figure 1.  Administration of soluble HEL by mini-osmotic  pumps in- 
hibits T  cell proliferation to dominant and subdominant HEL epitopes. 
BALB/c mice (three mice per group) were left untreated (i) or were im- 
planted with a mini-osmotic pump containing  PBS (O), 20 nmol P,  Nase/ 
mouse ([]), or 20 nmol HEL/mouse (O). 12 d after pump implantation 
mice were primed into the hind footpads with HEL emulsified in CFA, 
and 8 d later pooled lymph node cells (4 X 10  s cells/well) were cultured 
in triplicate with the indicated concentrations ofHEL (A), HEL8-29 (C), 
HELl05-120 (D), or with 3 IzM of a set ofpeptides spanning the entire 
HEL sequence (B). 3 d later cells were pulsed for 8 h with [3H]thymidine. 
Data  are  expressed as  mean  [3H]thymidine incorporation  with  back- 
ground proliferation (usually  between 2 and 10 X 103 cpm) subtracted (di 
cpm).  Control proliferative responses to  10 I.tg/ml PPD were  234,068 
(i), 272,797 (O), 228,034 (U]), and 202,068 (O). Results are from one 
representative experiment out of eight performed. 
487  Gu&y et al. T  cell responses  to dominant  and subdominant  HEL epi- 
topes. The set of overlapping HEL peptides used defines a 
subdominant  epitope  included  in  the  HEL sequence  12- 
29,  and  a  dominant  one included in HEL sequence  107- 
116 (Fig. 1 B). The T  cell response to the former epitope is 
restricted by I-A  d molecules (19), whereas the latter is I-E  d- 
restricted  (20).  As shown in Fig.  1,  administration  of solu- 
ble HEL completely inhibits T  cell responses to both sub- 
dominant  and  dominant  HEL epitopes,  as  determined  by 
lack of proliferation to peptides 8-29 and 105-120, respec- 
tively. This effect is due to the delivery of HEL and not to 
the pump implantation itself since no differences were ob- 
served between  mice without pumps and mice implanted 
with pumps containing either PBS or RNase,  an irrelevant 
protein antigen.  Inhibition of HEL-specific T  cell prolifer- 
ation is long-lasting, as it is still present in LNC from mice 
implanted  with  pumps  6  mo  before  priming  with  HEL- 
CFA (data not shown). 
Inhibition of Th l  and Priming of Th2  Cells by  Continuous 
Protein Administration.  The  effect  of continuous  protein 
antigen administration on Thl/Th2 development in BALB/c 
mice was analyzed by antigen-specific production of IL-2, 
IFN-~/,  IL-4, and  IL-5 in cultures  of LNC from protein- 
CFA-primed mice. As shown in Fig. 2, A  and B, the HEL- 
specific  production  of both  IL-2  and  IFN-~/  was  pro- 
foundly  inhibited  in  LNC  from  mice  implanted  with 
pumps containing 20 nmol HEL and subsequently primed 
with 0.3 nmol HEL-CFA, as compared to LNC from mice 
treated with PBS or RNase.  Conversely, a very high pro- 
duction of IL-4 (up to 4.5 ng/ml) was found in culture su- 
pernatants  of HEL-stimulated  LNC  from  mice  receiving 
soluble HEL, much higher than that induced in LNC from 
mice receiving PBS or P,.Nase  (124-322 pg/ml)  (Fig. 2,  C 
and D). Comparable results were found for IL-5. These ef- 
fects  are  specific  for the  soluble  antigen  administered  and 
are not restricted to HEL (Fig. 3). The increased IL-4 pro- 
duction  in  vitro  by  T  cells  from  soluble  antigen-treated 
mice is not a consequence of the inhibition of IFN-~/pro- 
duction, as demonstrated by the failure of XMG1.2  to en- 
hance  IL-4 production by T  cells from control mice  (not 
shown). Antigen-specific inhibition of Thl  and priming of 
Th2  cells  is  induced  by  any  antigen  tested,  including 
lkNase (Fig. 3, A-D), OVA (Fig. 3, E-H), human transfer- 
fin, and human hemoglobin (not shown).  In all cases,  con- 
tinuous  administration  of soluble  proteins  induces  inhibi- 
tion of T  cell proliferation associated with a strong reduction 
in  the  production  of the  Thl-associated  cytokines  (IL-2 
and  IFN-~/)  and  with  a  dramatic  up-regulation  of Th2- 
associated cytokines (IL-4 and IL-5). 
Th2 cells favor the production of IgG1 and IgE isotypes, 
while IgG2a and IgG2b are associated with Thl  cells.  Re- 
sults  in Table  1 show that in mice receiving soluble  HEL 
delivered by mini-osmotic pumps the production of HEL- 
specific IgG2a/IgG2b isotypes is strongly inhibited  ("o100- 
to  1,000-fold  decrease),  whereas  anti-HEL  antibodies  of 
IgG1  isotype  are  less  affected  (3-  to  10-fold  reduction), 
demonstrating inhibition of Thl  cell function in vivo. 
T  cell anergy has been  shown  to be  a  possible  mecha- 
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Figure 2.  Inhibition of Thl and stimulation of Th2 cells by continuous 
administration of soluble HEL. BALB/c mice were implanted with mini- 
osmotic pumps containing PBS (￿9  20 nmol RNase/mouse (Q), or 20 
nmol HEL/mouse (D), and immunized subcutaneously 12 d later into the 
hind footpads with HEL in CFA (0.3 nmol/mouse). At day 21, pooled 
popliteal lymph node cells (6 ￿  10  s cells/well) from two mice per group 
were cultured with the indicated concentrations of  HEL, and supematants 
assayed for cytokine production. IL-2 concentration (A) was determined 
in supematants collected after 20 h of culture using a CTLL proliferation 
assay. IFN-y (B), IL-4 (C), and IL-5 (D) production were assessed by 
two-sites sandwich ELISA in culture supematants collected at 72 h. Re- 
suits are from one representative experiment out of  seven performed. 
nism for induction of T  cell unresponsiveness after admin- 
istration  of antigen in nonimmunogenic form (21),  How- 
ever,  addition  of IL-2  in  vitro  could  restore  neither  the 
proliferative response nor IFN-~ production in LNC from 
mice treated with soluble antigen (data not shown). 
Collectively, these results show that continuous adminis- 
tration by mini-osmotic pumps of any native protein tested 
results  in  an  antigen-specific  block  of Thl  cells  and  in 
priming  of Th2  cells.  The  inhibition  of proliferative  re- 
sponse and IFN-',/production is not reversed by IL-2 addi- 
tion, suggesting that the mechanism of Thl  cell unrespon- 
siveness does not involve anergy induction in vivo. 
IL-4-producing  Cells Are  Fully  Differentiated  CD4+Th2 
Cells with Stable Cytokine Profile.  To  establish  the  cellular 
source  of IL-4,  we  first  tested  the  capacity  of anti-CD4 
mAb GK1.5  to prevent its production  in vitro.  As shown 
in  Table  2,  addition  of GK1.5  to  cultures  of LNC  from 
mice treated with soluble HEL abrogates the HEL-specific 
production of [L-4. No inhibition  is observed in the pres- 
ence  of anti-CD8  mAb  (KT1.5)  or isotype  control  mAb 
(not  shown).  To  analyze  further  the  phenotype  of IL-4- 
producing cells,  T  cell lines  were  generated from in vitro 
primary  cultures  of immune  LNC  from  individual  mice 
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Figure  3.  The  polarization  of T 
cell response ~om Thl to Th2 phe- 
notype is antigen specific and can be 
induced  by  any  soluble  protein 
tested. In A-D, BALB/c mice were 
implanted with mini-osmotic pumps 
containing  PBS  (O),  20  nmol 
RNase/mouse  (Q),  or  20  nmol 
HEL/mouse  (V1), corresponding  to 
"300 I-~g protein.  In E-F, BALB/c 
mice  were  implanted  with  mini- 
osmotic pumps containing PBS (O), 
or 400  I~g OVA/mouse (Q).  12  d 
after pump implantation,  mice were 
immunized  with  1  nmol  RNase 
(A-D)  or  15  I~g  OVA  (E-F)  in 
CFA.  Immune  LNC  pooled  from 
two mice per group were cultured at 
4 ￿  10  s cells/well  (A and E) or 6 ￿ 
105 cells/well (B-D, F-H) with the 
indicated  antigen  concentrations.  T 
cell proliferation  (A and E) was mea- 
sured  as  in  Fig.  1.  Antigen-driven 
IFN-y  (B and  F),  IL-4  (C and  G) 
and IL-5 (D and H) production were 
assayed in 72 h  culture  supematants 
by ELISA as in  Fig.  2.  Results  are 
from two representative experiments 
out of six performed. 
treated with continuous administration of PBS or of soluble 
HEL. After the initial 3-d culture period, LNC from all in- 
dividual mice tested showed the expected cytokine profile 
(Fig.  4,  A  and  B).  Cells  were  then  expanded  in  complete 
medium  without  addition  of exogenous  cytokines  and  re- 
stimulated  after  7  d  with  mitomycin  C-treated  BALB/c 
spleen cells as APC and HEL. As shown in Fig. 4,  C  and D, 
cells from  control  mice produce  high levels of IFN-y  and 
low amounts  of IL-4.  Reciprocally,  the  opposite  cytokine 
profile  is  secreted  by  cells from  mice treated  with  soluble 
HEL.  After another  9  d  in culture,  lines were  restimulated 
Table  1.  Anti-HEL Antibody  Isotypes in BALB/c Mice 
Treated with Soluble HEL 
Anti-HEL antibody concentration 
with APC and antigen for 4 d, then expanded in medium 
containing IL-2 for 5 d before being tested for HEL-spe- 
cific cytokine production.  Results  in  Fig.  5  A  show  the 
dose-response  curves  of IFN-y  and  IL-4  production  for 
four  representative  T  cell  lines  upon  restimulation  with 
HEL  and  APC.  T  cell lines  (TCL)  from  control mice  se- 
crete  intermediate  to  high  levels of IFN-~/  (2-80  ng/ml). 
IL-4 was produced by TCL  Nos.  11, but was low or absent 
in culture  supematants  from TCL  Nos.  12 and  13,  respec- 
tively.  Conversely,  IFN-y  production  is  undetectable  in 
any  TCL  derived  from  mice  treated  with  soluble  HEL, 
whereas  they  all produce  high  levels  (up  to  3.5  ng/ml)  of 
IL-4.  All  these  T  cell  lines  were  composed  of  CD4+/ 
Table 2.  Antigen-induced IL-4 Production Is Blocked by 
anti-CD4 mAb 
Soluble Ag  IgG  IgG1  IgG2a  IgG2b  IL-4 
HEL  no mAb  Anti-CD4  Anti-CD8 
R.Nase 
HEL 
U/mI 
45,966  29,900  2,952  917 
t8,500  16,090  409  279 
26,173  23,723  339  507 
1,226  1,412  <1  9.7 
1,802  2,103  <1  <1 
1,392  1,611  <1  <1 
~M  pg/mt 
10  660  <15  540 
1  381  <15  382 
0  <15  <15  <15 
BALB/c mice were implanted with pumps containing RNase or HEL 
(20 nmol/pump), and 12 d later immunized with HEL-CFA (3 nmole/ 
mouse).  After 9 d, mice were bled and sera analyzed  for HEL-specific 
antibodies  by ELISA. Results are expressed as serum antibody concen- 
tration  in units  per milliliter in individual  mice. Results are from one 
representative  experiment out of three performed. 
BALB/c mice implanted with pump containing 20 nmol HEL/mouse 
were subsequently  immunized with HEL-CFA (1  nmol/mouse). 9  d 
later, LNC were cultured with the indicated concentrations of HEL, in 
the  presence  of 5  ~g/ml  purified  anti-CD4  (GK1.5)  or  anti-CD8 
(KT1.5)  mAb. IL-4 production was assessed in 72-h culture supema- 
tants by ELISA as in Fig. 3. Results are from one representative  experi- 
ment out of three performed. 
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Figure 4.  Generation of antigen-specific Thl and Th2 cell lines, hn- 
mune LNC were obtained from individual I3ALB/c  mice (three mice per 
group) implanted with pumps containing PBS or 20 nmol HEL/mouse, 
12 d before immunization with HEL in CFA (0.3 nmol/mouse) and cul- 
tured at 6 ￿  10  s cells/well in the presence of 10 IxM HEL. Culture su- 
pernatants from triplicate cultures were harvested at 72 h and tested for 
IFN-~/ (A) and IL-4 (B) production by ELISA. In C and D, cells from the 
primary culture were expanded in complete medium and then tested at 
day 7 for cytokine production. They were cultured at 5 ￿  1(14 cells/well 
in the presence of mitomycin C-treated BALB/c spleen cells (3 ￿  10s/ 
well) and 10 IxM HEL. Culture supernatants from triplicate cultures were 
harvested at 48 h and tested for IFN-',/ (C) and IL-4 (D) production by 
ELISA. 
CD8-  cells  expressing  similar  amounts  of TCRe~/[3  and 
CD3 molecules as detected by FACS  |  analysis. A  represen- 
tative  double  staining  with  anti-CD4  and  anti-TCR{x/[3 
m_Ab is shown for TCL Nos.  13 and 23 in Fig. 5 B. 
Low Dose Soluble Proteins, including Extracts  from Pathogens, 
Induce Antigen-specific Default Th2 Cell Development in BALB/c 
Mice.  So far, experiments were performed with relatively 
high doses  of protein  antigen loaded in pumps  ('-'~300  I~g 
protein/pump)  delivering  ,'~30  p~g protein/d.  Therefore, 
we  next  tested  the  effect  of low  dose  soluble  antigen  ad- 
ministration  on the  polarization  of Th  subsets  in BALB/c 
mice.  As  shown  in  Fig.  6,  continuous  administration  of 
400-4 p~g OVA per mouse results in a complete inhibition 
of IFN-~/ production after restimulation  of immune  LNC 
with OVA in vitro.  Conversely, induction of IL-4-secret- 
ing  cells  is  dose  dependent  and  it  is  maximum  for  low 
rather  than  high doses  of protein.  Administration  of 4  p~g 
OVA/pump,  corresponding  to  a  protein  delivery  of 0.4 
I.tg/d,  is  still  able  to induce  high  levels  of Thg-associated 
cytokines IL-4 and IL-5. As shown in Fig. 7, similar results 
are obtained with  other protein antigens.  In Fig.  7, A  and 
B, HEL-specific production of IFN-~ was blocked by any 
dose  of soluble  HEL administered,  whereas  maximum  in- 
duction  of antigen-specific  IL-4 production  was  observed 
at the lowest HEL dose tested  (0.8 nmol  =  10 Ixg/pump) 
corresponding to an HEL delivery of I  p~g/d. 
To  address  the  relevance  of these  observations  in  the 
pathogenesis  of chronic  infectious  diseases,  we  tested  the 
ability of pathogen-derived crude soluble extracts adminis- 
tered by mini-osmotic pumps to induce Th2 development 
in'BALB/c mice. PPD represents a model system in this re- 
spect, as it is derived from pathogenic microorganisms and 
T  cell responses can be easily induced by immunizing mice 
with Freund's adjuvant containing heat-killed M.  tuberculo- 
sis. Administration of soluble PPD by mini-osmotic pumps 
readily  induces  PPD-specific  IL-4 production,  highest  at 
the  lowest  dose  of PPD  administered,  while  IFN-'y pro- 
duction is inhibited  by any dose tested  (Fig.  7,  C  and D). 
Continuous  administration  of soluble  recombinant  65-kD 
hsp65,  a major antigen  of M.  tuberculosis (22),  to BALB/c 
mice also prevents  IFN-~/ production at both doses tested 
(100 and  10 big/pump), while IL-4 production is inversely 
related to the dose of soluble PPD administered,  the lowest 
dose  being  the  most  efficient  (Fig.  7,  E  and  F).  Similar 
results were obtained with soluble leishmania  antigen  (not 
shown). 
Taken together, these data show that continuous admin- 
istration  of proteins at low doses efficiently induces default 
Th2 development in BALB/c mice. The inhibition of Thl 
cell  induction  does  not  appear  to  be  dependent  on  the 
magnitude of Th2 cell priming.  Interestingly, a strong Th2 
response is induced even by soluble PPD, an antigen mix- 
ture known to preferentially  recall Thl-type cells  (3),  and 
by one of its purified components, hsp65. 
Blocking Endogenous IL-4 Prevents Th2 Cells Expansion but 
Do Not Restore Th I Cell Unresponsiveness.  To  address  whether 
IL-4 is required  in vivo for the  expansion  of antigen-spe- 
cific Th2 cells,  we examined the polarization of the T  cell 
response in mice pretreated  with soluble HEL in the pres- 
ence of 11B11 mAb and then immunized with HEL-CFA. 
Results  in  Fig.  8  show that  T  cells  from soluble  antigen- 
treated mice subsequently injected with a control rat mAb 
(LO-DNP-2)  have  a  reduced  capacity  to  secrete  IFN-y, 
while  IL-4 production is up-regulated upon restimulation. 
In contrast,  administration  of anti-IL-4 11B1 1 mAb at the 
time of soluble HEL delivery results m  almost complete in- 
hibition oflL-4 production by antigen-specific T  cells  (Fig. 
8  B)  and is not associated  with  a restoration  of IFN-y se- 
cretion (Fig. 8 A). Similar results were obtained using OVA 
as antigen (not shown). Taken together, these data demon- 
strate  that  blocking  endogenous  IL-4 inhibits  completely 
the development of IL-4 producing Th2 cells,  but does not 
reverse the block in IFN-',/-producing Thl  cells. 
Selective Induction  of Th2  Cells Depends on  Non-MHC- 
linked Genetic Polymorphism.  To  address  whether  induc- 
tion  of Th2 cells  in our model system is predictive  of dis- 
ease outcome after L. major  infection, we compared the effect 
of continuous protein administration  on Th2 development 
in the susceptible mouse strain BALB/c and in the resistant 
strains C3H,  C57BL/6, and DBA/2. PPD was chosen be- 
cause of its  capacity to induce comparable T  cell responses 
in  different mouse strains.  Results  in  Fig.  9  show that ad- 
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ministration of soluble PPD,  for any dose tested,  results in 
decreased  PPD-specific  IFN-~/  production by LNC  from 
both  CFA-immunized BALB/c  and  C3H  mice.  Interest- 
ingly,  this  treatment  leads  to  a  clear-cut  dose-dependent 
up-regulation of the production of the Th2-associated cy- 
tokine IL-4 in BALB/c  mice, whereas  this  effect is much 
less  evident in T  cells from  C3H  mice.  As shown in  Fig. 
10,  similar results  are  obtained in  the  other  strain tested. 
Again, a strong Th2 response is seen only in the susceptible 
BALB/c  mice,  as  compared  to  DBA/2  and  C57BL/6, 
whereas  IFN-~/production is inhibited in all strains. Since 
BALB/c and DBA/2  share the same H-2 haplotype, selec- 
tive induction of Th2  cells by soluble antigen administra- 
tion appears to depend on non-MHC-linked  genetic poly- 
morphism. 
Induction  of Th l  Unresponsiveness  and  Th2  Priming  Do 
Not Require CD8  + or CD4 + NK1.1 +  T  Cells,  Respectively. 
CD8 + T  cells have been shown to suppress T  cell prolifer- 
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Figure  5.  Thl  and Th2  cell 
lines are composed of TCRc~/[3, 
CD4 +  Th2  cells.  T  cell  lines 
generated  as described in Fig. 6 
were  rested  for  9  d  before  re- 
stimulation with APC and HEL. 
After another  4-d period, T  cell 
lines  were  expanded  with  me- 
dium containing  human rlL-2 (5 
ng/ml) before  being tested  5  d 
later for antigen-specific produc- 
tion of IFN-~/and IL-4 as in Fig. 
4.  Representative  T  cell  hnes 
from control (TCL#12 and #13) 
and  HEL-treated  (TCL#21  and 
#23)  mice are  shown in A.  B 
shows  cell  surface staining  of 
TCL Nos. 13 and 23 using anti- 
TCR-PE  and  anti-CD4-HTC 
mAb,  performed  after another 
round of rest and restimulation. 
ation in oral tolerance (23), while CD4 §  NK1.1 + cells are 
thought to produce the initial burst of IL-4 driving the dif- 
ferentiation of antigen-specifc CD4 +  T  cells into the Th2 
phenotype  (24).  Mice deficient for the  132M genes can be 
used  to  test the  relevance of both  cell types.  These  mice 
do not express MHC  class I molecules, which results in the 
lack of positive selection of CD8 +  T  cells (25)  and of the 
small population  of CD4 §  T  cells  expressing  the  NKI.1 
marker  (26,  27).  132M-deficient  BALB/c  mice  (seventh 
back-cross  generation)  were  implanted  with  pumps  con- 
taining soluble HEL  12  d  before  HEL printing. Like nor- 
mal BALB/c mice, 132M  -/-  mice mount a strong prolifer- 
ative  response  to  HEL,  associated with  the  production of 
IL-2  (not shown)  and IFN-~/  (Fig.  11  A),  while the  pro- 
duction of IL-4  (Fig.  11  B)  and IL-5  (not shown)  is rela- 
tively low. As shown for IFN-~/and IL-4  (Fig.  11, A  and 
B),  continuous administration of soluble  HEL  before  im- 
munization results in a  complete reversion of the cytokine 
3 
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Figure  6.  Continuous admin- 
istration of low dose soluble pro- 
tein can induce Th2 cell devel- 
opment.  BALB/c  mice  were 
implanted  with  mini-osmotic 
pumps  containing the  indicated 
amounts  of  soluble  OVA/ 
mouse,  12  d  before  immuniza- 
tion with 50 I~g OVA in CFA. 
Pooled LNC from two mice per 
group were  cultured at 6 ￿  l0  s 
cells/well in the presence of 30 
p,g/ml OVA, and IFN-*/(A), IL- 
4  (B), and  IL-5  (C)  production 
were measured by ELISA in cul- 
ture  supernatants  at  72  h  as  in 
Fig. 2. Results are from one rep- 
resentative  experiment  out  of 
three performed. 
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Figure  7.  Continuous administration of soluble extracts from myco- 
bacterium (PPD)  or one of its purified components (hsp65)  can readily 
induce Th2  cell response.  In A  and  B, BALB/c mice were implanted 
with mini-osmotic pumps containing 20 (O), 4 ([3), 0.8 (A) nmol soluble 
HEL/mouse, corresponding to 300,  60, and 10 Ixg/mouse, or PBS only 
(0). In C and D, mice were implanted with pumps containing PBS only 
(O),  or 400  (0),  80  (~),  16  (A)  txg soluble PPD/mouse. In E  and F, 
mice were implanted with pumps containing PBS only (0)  or 100  (O) 
and 10 (A) p,g soluble hsp65/mouse. 12 d after pump implantation, mice 
were immunized with the following antigen in CFA: 1 nmol HEL (A and 
B), CFA only (C and D),  or 10  ~g hsp65 (E and F).  9  d  later, pooled 
LNC from two mice per group were cultured at 6 X 10 s cells/well in the 
presence of the indicated antigens. IFN-'/ (.4, C, and E) and IL-4 (B and 
D) production were measured by ELISA in culture supematants at 72 h as 
in Fig. 2. In F, IL-4 production was assessed by proliferation of the IL-4- 
dependent CTL44 cell line. Data are expressed as [3H]thymidine incorpo- 
ration with background proliferation in the absence of antigen  (7,228- 
8,489 cpm) subtracted_  Results are from three representative experiments 
out of six performed. 
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Figure  8.  Blocking endogenous IL-4 in vivo inhibits Th2 cell induc- 
tion but does not restore IFN-~/production. BALB/c mice (two mice per 
group) were implanted with pumps containing either PBS (O) or 1 nmol 
HEL/mouse (A, [-1). At days 0, 4, and 8 of the experiment, animals were 
injected intraperitoneaUy with PBS  (@),  anti-IL-4  11Bll  mAb (D),  or 
control LO-DNP-2  mAb (A). At day  12,  mice were immunized with 
HEL in CFA (3 nmol/mouse) and the polarization of the T  cell response 
tested 9 d later as in Fig. 2. Data are from one representative experiment 
out of three performed. 
pattern  produced  by  ~2M -/-  immune  LNC  restimulated 
with  antigen in vitro,  comparable  to  that  observed  in nor- 
mal BALB/c  mice.  Similar data were  obtained  using as an- 
tigen PPD  (Fig,  11,  C  and D) and OVA  (data not shown). 
Therefore,  these  results  demonstrate  that  inhibition  of 
Thl  and priming  of Th2  cells by continuous  administration 
of either purified proteins or crude soluble protein  extracts 
from pathogens  does not require expression of MHC  class I 
molecules, ruling out  a  role for CD8 +  and CD4 +  NKt.1  + 
T  cells. 
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Figure 9.  Genetic predisposition determines Th2 cell development in 
mice treated with continuous administration of solubIe antigen. BALB/c 
or C3H mice were implanted with mim-osmotic pumps containing the 
indicated amount ofsnluble PPD in PBS, 2 wk before irmnunization with 
CFA only.  Immune LNC,  pooled from two mice per group, were re- 
stimulated in vitro with 30 p.g/ml PPD. [FN-3' (.4) and IL-4 (B) produc- 
tion was assessed in 72-h culture supernatants by ELISA. Data are from 
one representative experiment out of three performed. 
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Figure  10.  Non-MHC genes amplify the Th2 
cell response in BALB/c mice. BALB/c (.4 and B), 
DBA/2 (C and D),  or C57BL/6  (E and F) mice 
were implanted with mini-osmotic pumps contain- 
ing 100 (O) or 10 (A) Ixg soluble PPD/mouse, or 
left untreated  (O).  3 wk later, they were  immu- 
nized with 10 I.Lg PPD in IFA. Pooled LNC from 
two mice per group were cultured in the presence 
of the indicated concentrations of PPD. IFN-~/ (A, 
C, and E) and IL-4 (B, D, and F) production were 
measured in culture supernatants at 72 h as in Fig. 
2. Data are from one representative experiment out 
of three perforated. 
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Figure  11.  Inhibition of Thl and priming of Th2 cells do not require 
CD8 + or CD4+NK1.1 + T  cells. In A and B, BALB/c mice (two mice 
per group) with disrupted [32M genes were implanted with mini-osmotic 
pumps containing PBS only (O) or 20 nmol HEL/mouse (Q). In C and 
D, [32M-deficient mice were implanted with pumps containing PBS (￿9 
or 30 Wg soluble PPD/mouse (Q). At day 12 mice were immunized with 
1 nmol HEL in CFA (A and B) or CFA only (C and D). 9 d later, T cell 
responses to the indicated antigens were assessed. IFN-~ (A and C) and 
IL-4 (B and D) production were measured in culture supernatants at 72 h 
as in Fig. 2. Results are from two representative experiments out of five 
performed. 
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Discussion 
Since the initial observations by Parish and Liew (28) on 
the dichotomy of the immune response and the demonstra- 
tion by Mosmann et al.  of Thl  and Th2  cells,  defined by 
their  different  lymphokine  production  pattern  (1),  it  has 
became increasingly clear that immune responses are often 
dominated  by  either  type  of  IFN-y  or  IL-4-producing 
CD4 + T  cells. For instance, protective immunity is associ- 
ated with a Thl  rather than a Th2 pattern of cytokine pro- 
duction  in  lesions  caused  by M.  leprae (10).  Similarly,  in 
most mouse strains, infection by the parasite L. major leads 
to  a  dominant Thl-type  immune  response  and  results  in 
elimination  of the  pathogen.  In  contrast,  BALB/c  mice 
mount a predominantly humoral immune response, associ- 
ated  with  induction of Th2-type  lymphocytes  producing 
IL-4 and IL-10, which is ineffective in controlling parasite 
growth (6, 29).  This is not due to an intrinsic incapacity of 
leishmania-specific CD4 + T  cells in these mice to differen- 
tiate  into  Thl-type  lymphocytes,  because  a  protective 
Thl-type immune response could be obtained by blocking 
endogenous  IL-4  (30)  or  by  providing  exogenous  IL-12 
(31). Actually, L. major-infected  BALB/c mice contain an- 
tigen-specific Thl  cells whose  functions are  actively sup- 
pressed by the dominant Th2 population (32), but the ini- 
tial  mechanisms  leading  to  the  preferential  activation  of 
these Th2 cells are still unclear. 
As a possible explanation, we hypothesized that infection 
by microorganisms would result in a  continuous release of 
pathogen-derived proteins,  skewing the  immune response 
in BALB/c mice toward a Th2 phenotype. To test this hy- 
pothesis, we established an experimental model using mini- 
osmotic pumps as antigen delivery system. As shown in the 
present paper for defined protein antigens and crude solu- ble extracts from pathogenic microorganisms, the continu- 
ous release of soluble proteins leads, in BALB/c mice, to a 
strong inhibition  of antigen-specific Thl  cells  and  to  the 
priming of Th2-type helper T  cells.  Selective priming of 
Th2 cells is associated with reduction of protein-specific T 
cell proliferation,  in  agreement with  the  observation that 
IL-4 production  can be observed in the  absence of T  cell 
proliferation (33). 
These  results  have  implications  for the  pathogenesis  of 
infectious diseases.  First,  the  amount  of IL-4 produced  in 
our model (up to 5  ng/ml) is comparable to that secreted 
by immune LNC from L.  major-infected mice (32).  This is 
achieved in  mice primed with protein  emulsified in  CFA 
which favors induction of Thl-type cells; adjuvants such as 
IFA or alum might promote even higher Th2  cell induc- 
tion. Second, antigen-specific IL-4--producing Th2 cell lines 
could  be  easily  obtained  in  the  absence  of exogenously 
added cytokines.  These cell lines maintained their pheno- 
type  upon  several  weeks  in  culture  showing  that  they 
were  derived  from Th2  cells  fully  differentiated  in  vivo. 
Third,  priming of antigen-specific Th2  cells  could be in- 
duced by any soluble antigen tested, including crude solu- 
ble extracts from pathogens such as M.  tuberculosis or solu- 
ble leishmania  antigen.  Finally,  Th2  priming,  unlike  Thl 
inhibition,  appears  to  depend  on  genetic  predisposition, 
and  it  is  not  observed in  the  L.  major-resistant  C3H  and 
C57BL/6 mouse strains. 
Controversial results have been obtained by studying the 
effect of soluble  antigen  administration  on  Thl/Th2  ceil 
development  (34--37).  In some instances,  antigen-specific 
unresponsiveness  induced  by  pretreatment  with  aqueous 
antigen selectively tolerized Thl but not Th2 cells (34,  35), 
while in other reports both Th subsets were inhibited  (36, 
37).  A  common feature of all these studies is the modest 
or  hardly  detectable  amount  of IL-4  produced  (38,  39). 
Aside from the fact that high dose soluble hapten-protein 
conjugates  (35)  or high molecular weight proteins such as 
deaggregated human ",/-globulin (34, 36) or KLH (35) were 
used,  none  of these  studies  was  carried  out  in  BALB/c 
mice. Therefore, the lack of evidence for a strong priming 
of Th2  cells  in these models could be easily explained by 
the mouse strains used,  the  high doses of antigen injected 
(>1  mg)  and  the  mode  of soluble  antigen  administration 
(single  or repeated bolus injection).  In fact, we observed an 
inverse  correlation  between  the  dose  of antigen  adminis- 
tered by mini-osmotic pumps and  the  level of IL-4 pro- 
duced in vitro by immune LNC. Doses of 400-4  Ixg pro- 
tein/pump  induced  complete blockade  of Thl  responses, 
but at lower doses reappearance of IFN-y-producing cells 
was  observed.  Maximal  IL-4  production  was  reached  at 
protein doses between  100  and 4  btg/pump, but a signifi- 
cant  IL-4 production  was still  induced  by doses  <1  L~g/ 
pump, corresponding to 100 ng/d (Gu6ry, J-C., et al.,  un- 
published observations). Due  to the reappearance of IPN- 
y-producing cells,  which have been shown to inhibit Th2 
cell proliferation in vitro (40),  it is likely that induction  of 
Th2 responses induced by very low doses of soluble protein 
is  underestimated.  The amount  of pathogen-derived pro- 
teins in  the  circulation  is likely to be correlated with  the 
type and load of infecting microorganisms. Only for high 
level of infection the threshold concentration necessary for 
Th2-priming would be reached.  Below this  threshold  no 
Th2 development would occur, consistent with the obser- 
vation that low level infection preferentially induces  pro- 
tective immunity in BALB/c mice (9). 
Priming of Th2  cells in our model is dependent  on the 
presence of endogenous IL-4, since administration of 11B11 
mAb at the time of continuous antigen administration pre- 
vents Th2 cell expansion. Thus, the polarization of the re- 
sponse towards  a  Th2  phenotype  in BALB/c  mice could 
depend  on  the  initial  activation  of IL-4-producing  cells 
such as the CD4+NKI.1 + population (24).  This is unlikely 
since  similar  results  were  obtained  in  ]32M-deficient 
BALB/c mice, lacking this cell population whose develop- 
ment  depends  on  MHC  class  I  expression  (26,  27).  The 
IL-4 required  for Th2  priming in  vivo  rather  appears  to 
be produced  by  conventional  antigen-specific  class  II- 
restricted CD4 + T  cells.  Th2 cells might develop after the 
initial  activation of a rare population  expressing particular 
phenotypic markers (e.g., LECAM-1 dujl) and able to secrete 
significant  amounts  of IL-4  upon  primary stimulation  in 
vitro (41-43). 
The APC type presenting soluble antigen may also play a 
role in selectively priming Th2  cells.  Induction of experi- 
mental allergic encephalomyelitis, a Thl-mediated autoim- 
mune disease, has been prevented by targeting the autoan- 
tigen to B  cells  (44),  and this prevention has been recently 
found to be associated with the priming of antigen-specific 
Th2  cells  (45).  Therefore,  antigen  presentation  by  APC 
lacking appropriate costinmlatory molecules such as B  cells 
during a noninflammatory immune response could inhibit 
Thl  and induce Th2 development. IgD targeting on the B 
cell surface by bivalent antibody fragments results in B  cell 
activation (46),  which  might be a prerequisite for priming 
of  Th2  cells  (45).  However,  Th2  development  in  our 
model is observed in the absence of any exogenous manip- 
ulation,  e.g.,  administration  of cytokines  or  anticytokine 
antibodies, or antigen targeting to any particular APC, and 
rather represents the default pathway ofT helper cell differ- 
entiation in a particular mouse strain. 
The preferential differentiation of antigen-specific CD4 + 
T  cells into IL-4-producing cells might depend on the non- 
MHC-linked  genetic  predisposition  of BALB/c  mice  to 
develop Th2 cells (47). Evidence for this is provided by the 
observation that continuous  administration of soluble pro- 
tein induces a strong Th2 response in BALB/c but not in 
DBA/2,  C3H,  or  C57BL/6  mice,  whereas  the  Thl  re- 
sponse is inhibited  in  any mouse strain  tested.  These data 
offer an  explanation  for  the  previous  conflicting  results 
describing  selective  inhibition  of Thl  but  not  Th2  re- 
sponses (34,  35)  or inhibition  of both Th subsets (36,  37) 
by pretreatment with soluble antigen. The commitment to 
Th2  cell differentiation in BALB/c mice may result from 
failure of IL-12 to  induce  phosphorylation of Jak2,  Star3, 
and Stat4 in Th2  cells,  leading to extinction of IL-12 sig- 
naling (48). 
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suppressor T  cells was found to be an important mechanism 
for T  cell unresponsiveness (23, 49). This is not the case af- 
ter  continuous  subcutaneous  administration  of  antigen, 
since a similar inhibition of Thl  cells was obtained in nor- 
mal  BALB/c  mice  and  in  mice  lacking  CD8 +  T  cells. 
While induction of CD8 + suppressor T  cells can be defini- 
tively  ruled  out,  immunoregulation  by  antigen-specific 
Th2 cells could play a role in our model. Upon immuniza- 
tion with antigen in adjuvant,  the primed Th2 population 
could then be preferentially expanded and influence further 
differentiation  of naive Th cells in situ by the secretion of 
IL-4 and IL-10 (50). 
Based on our present results,  it appears that the polariza- 
tion of the immune response  towards a Th2 phenotype is 
mediated by a dual mechanism: induction of Thl  cell un- 
responsiveness  and default development  of Th2  cells.  The 
different  antigen  dose  dependence  of these  two  events  in 
BALB/c mice suggests that, after continuous administration 
of soluble proteins, these two pathways may develop inde- 
pendently.  This is further supported by two sets of experi- 
ments.  First, blocking endogenous IL-4 during continuous 
administration  of soluble antigen to BALB/c mice inhibits 
Th2 cell development, but does not reverse the inhibition 
of Thl  cells.  Second, the inhibition  of the Thl  response is 
unrelated to the development of a strong Th2 response,  as 
indicated by data obtained in different mouse strains. 
In  conclusion,  we  have  demonstrated  that  continuous 
administration of soluble antigen to BALB/c mice induces 
a polarization of the immune response towards a Th2 phe- 
notype.  This  finding  might  have  implications  for  under- 
standing  the  pathogenesis  of chronic  infectious  diseases 
mediated  by organisms  as  diverse  as  helminths,  protozoa, 
bacteria,  and retroviruses, where infection is frequently ac- 
companied  by  down-regulation  of host  defense  and  in- 
creased production ofTh2-type cytokines (51). 
J.-C.  Gu&y is supported  by a Human  Capital  and  Mobility fellowship  from the European Community 
(ERBCHR.XCT920008). 
Address correspondence  to L. Adorini, Roche Milano Ricerche, Via Olgettina  58, 1-20132 Milano,  Italy. 
Received  for publication  26 May  1995 and in revised  form  18 September 1995. 
References 
1. Mosmann,  T.R.,  and  R.L.  Coffrnan.  1989.  Thl  and  Th2 
cells: different patterns  oflymphokine secretion lead to differ- 
ent functional properties.  Annu. Rev. Immunol. 7:145-173. 
2.  Fowell,  D., A.J. McKnight, F. Powrie, R. Dyke, and D. Ma- 
son.  1991.  Subsets ofCD4  + T  cells and their roles in the in- 
duction and prevention ofautoimmunity. Immunol. Rev.  123: 
37-64. 
3.  Del Prete, G.F., M. De Carli,  C. Mastromauro, R. Biagiotti, 
D. Macchia,  P. Falagiani, M. Ricci, and S. Romagnani. 1991. 
Purified  protein  derivative  of Mycobacterium tuberculosis and 
excretory-secretory  antigen(s)  of Toxocara canis expand  in 
vitro human T cells with stable and opposite (type 1 T helper 
or type 2 T  helper)  profile  of cytokine production. J.  Clin. 
Invest. 88:346-350. 
4.  Trinchieri, G.  1993. Interleukin-12 and its role in the gener- 
ation of Thl cells. Immunol. Today. 14:335-338. 
5.  Paul,  W.E.,  and R.A.  Seder.  1994.  Lymphocytes responses 
and cytokines. Cell. 76:241-251. 
6.  Heinzel, F.P., M.D. Sadick, B.J. Holaday, R.L. Coffman, and 
R.M. Locksley.  1989.  Reciprocal expression  of interferon 3, 
or interleukin 4 during the resolution or progression of mu- 
rine leishmaniasis.  Evidence for expansion of distinct  helper 
T cell subsets.J.  Exp. Med. 169.59-72. 
7.  Pearce,  E.J., P. Caspar, J.M. Grzych, F.A. Lewis, and A. Sher. 
1991.  Downregulation of Thl  cytokine production accom- 
panies  induction  of Th2  responses  by a parasitic  helminth, 
Schistosoma mansoni.J. Exp. Med. 173:159-166. 
8. Bancroft, A.J., K.J. Else, and R.K. Grencis.  1994. Low-level 
infection with Trichuris muris significantly affects the polariza- 
tion of the CD4 response.  Eur.J. Immunol. 24:3113-3118. 
495  Gu&y et al. 
9. Bretsher,  P.A.,  G.  Wei,  J.N.  Menon,  and  H.  Bielefeldt- 
Ohmann.  1992.  Establishment  of stable, cell-mediated  im- 
munity that makes  "susceptible"  mice resistant to Leishmania 
major. Science (Wash. DC). 257:539-542. 
10. Yamamura,  M.,  K.  Uyemura,  R.J.  Deans,  K.  Weinberg, 
T.H.  Rea,  B.R.  Bloom,  and R.L.  Modlin.  1991.  Defining 
protective responses to pathogens: cytokine profiles in leprosy 
lesions. Science (Wash. DC). 254:277-279. 
11. Grzych, J.M., E. Pearce,  A. Cheever, Z.A. Caulada,  P.  Cas- 
par, S. Heiny, F. Lewis, and A. Sher.  1991. Egg deposition is 
the major stimulus  for the production of Th2  cytokines in 
murine schistosomiasis mansoni. J. Immunol. 146:1322-1327. 
12. Zijlstra,  M., E. Li, F. Sajjadi, S. Subramani,  and R. Jaenisch. 
1989. Germ-line transmission  of a disrupted [~2-microglobu- 
lin gene produced by homologous recombination in embry- 
onic stem cells. Nature (Lond.). 342:435-438. 
13. Wells,  F.B.,  S.-J.  Gahm,  S.M.  Hedrick, J.A.  Bluestone,  A. 
Dent, and L.A. Matis.  1991. Requirement for positive  selec- 
tion of~/8 receptor-bearing T cells. Science (Wash. DC). 253: 
903-905. 
14. Gu~ry, J.C.,  and  L.  Adorini.  1995.  Dendritic  cells are  the 
most efficient  in presenting endogenous naturally  processed 
self-epitopes  to  class lI-restricted  T  cells. J.  Immunol. 154: 
536-544. 
15. Tomonari, K., and S. Spencer.  1990. Epitope specific binding 
of CD8 regulates activation of T cells and induction of cyto- 
toxicity. Int. Immunol. 2:1189. 
16. Prat,  M.,  G.  Gribaudo,  P.M.  Comoglio, G.  Cavallo,  and S. 
Landolfo. 1984. Monoclonal antibodies  against murine ",/in- 
terferon. Proc. Natl. Acad. Sci. USA. 81:4515-4519. 17. Cherwinski, H.M., J.H. Shumacher, K.D. Brown, and T.1K. 
Mosmann. 1987.  Two types  of mouse helper T  cell clone. 
III. Further differences in lymphokine synthesis between Thl 
and Th2 clones revealed by 1KNA hybridization, functionally 
monospecific bioassays, and monoclonal antibodies. J.  Exp. 
Med. 166:1229-1244. 
18. Favre, N., and P.  Erb.  1993. Use of the CTL44 cell line, a 
derivative of CTL/L cells, to identify and quantify mouse in- 
terleukin-4 by bioassay.J.  Immunol. Methods. 164:213-220. 
19. Gammon,  G.,  H.M.  Geysen,  R.J.  Apple,  E.  Pickett,  M. 
Palmer,  A. Ametani, and E.E.  Sercarz. 1991. T cell determi- 
nant  structure:  cores  and  determinant envelopes  in  three 
mouse major histocompatibility complex haplotypes. J.  Exp. 
Med.  173:609-617. 
20. Adorini, L., A. Sette, S. Buus,  H.M. Grey, M. Darsley, P.V. 
Lehmann, G. Doria, Z.A. Nagy, and E. Apella.  1988. Inter- 
action of an immunodominant epitope with Ia molecules  in 
T cell activation.  Proc. Natl. Acad. Sci. USA. 85:5181-5185. 
21. Gaur, A., B. Wiers, A. Liu, J. 1Kothbard, and C.G. Fathman. 
1992.  Amelioration of autoimmune  encephalomyelitis by 
myelin basic protein synthetic peptide-induced anergy.  Sci- 
ence (Wash. DC). 258:1491-1494. 
22. Kaufmann, S.H.E.,  U. V~th, J.E.R. Thole, J.D.A. Van Emb- 
den, and F. Emmrich. 1987. Enumeration ofT cells reactive 
with Mycobacterium tuberculosis organisms  and specific for the 
recombinant mycobacterial  64-kDa protein. Eur. J.  Immunol. 
17:351-357. 
23. Lider, O., L.M.B.  Santos, C.S.Y.  Lee, D.J. Higgins, and H.L. 
Weiner. 1989. Suppression of experimental autoimmune en- 
cephalomyelitis by oral administration of myelin basic protein 
II. Suppression of disease and in vitro response is mediated by 
CD8 + T lymphocytes. J. Immunol. 142:748-752. 
24. Yoshimoto,  T.,  and E.P.  Paul.  1994. CD4  p~  NKI.lP  ~  T 
cells promptly produce interleukin 4 in response  to in vivo 
challenge with anti-CD3.J. Exp. Med.  179:1285-1295. 
25. Zijlstra, M., M. Bix, N.E. Simister, J.M. Loring,  D.H. 1Kau- 
let, and IK. Jaenisch.  1990. ]32-microglobulin deficient mice 
lack CD4-8 + cytolytic T cells. Nature (Lond.). 344:742-746. 
26. Bendelac,  A., N. Killeen, D.L. Littman, and R.H. Schwartz. 
1994. A subset ofCD4 + thymocytes selected by MHC class I 
molecules.  Science (Wash. DC). 263:1774-1778. 
27. Coles, M.C., and D.H. Raulet. 1994. Class I dependence of 
development of CD4 + CD8-  NK1.1 + thymocytes. J.  Exp. 
Med.  180:395-399. 
28. Parish,  C.R.,  and  F.Y.  Liew.  1972.  Immune response  to 
chemically  modified  flagellin.  III.  Enhanced  cell-mediated 
immunity during high and low zone antibody tolerance to 
flagellin.J. Exp. Med.  135:298-311. 
29. Scott, P., P. Natovitz, 1K.L. Coffman, E. Pearce, and A. Sher. 
1988.  Immunoregulation of cutaneous leishmaniasis. T  cell 
lines  that  transfer  protective immunity or exacerbation be- 
long to different T helper subsets and respond to distinct par- 
asite antigens.J. Exp. Med.  168:1675-1664. 
30. Sadick,  M.D.,  F.P.  Heinzel, B.J. Holaday,  IK.T.  Pu,  1K.S. 
Dawkins, and R.M.  Locksley.  1990.  Cure of murine leish- 
maniasis  with  anti-interleukin 4  monoclonal antibody. J. 
Exp. Med.  171:115-127. 
31. Heinzel, F.P.,  D.S.  Schoenhaut, 1K.M. Rerko,  L.E.  Rosser, 
and M.K.  Gately.  1993. Recombinant interleukin 12  cures 
mice infected with Leishmania major. J.  Exp.  Med.  177:1505- 
1509. 
32. Powrie,  F.,  R.  Correa-Oliveira, S.  Mauze,  and R.L.  Coff- 
man.  1994.  Regulatory  interactions between  CD45RB  aigh 
and CD45RB  l~  CD4 + T cells are important for the balance 
between protective immunity and pathogenic cell-mediated 
immunity._/. Exp. Med.  179:589-600. 
33. Evavold, B.D.,  and P.M.  Allen.  1991.  Separation  of IL-4 
production from Th cell proliferation by an altered T cell re- 
ceptor ligand. Science (Wash. DC). 252:1308-1310. 
34. De  Wit,  D.,  M.  Van  Mechelen,  M.  Ryelandt,  A.C. 
Figneiredo, D. Abramowicz, M. Goldman, H. Bazin, J.  Ur- 
bain,  and  O.  Leo.  1992.  The  injection  of  deaggregated 
gamma globulins in adult mice induces antigen-specific  unre- 
sponsiveness of T helper type  1 but not type 2 lymphocytes. 
J. Exp. Med. 175:9-14. 
35. Burstein, H.J.,  C.M.  Shea, and A.K. Abbas.  1992. Aqueous 
antigens induce in vivo  tolerance selectively  in IL-2- and 
IFN-"/-producing (Thl) cells.J,  lmmunol. 148:3687-3691. 
36. Romball, C.G., and W.O. Weigle. 1993. In vivo induction 
of tolerance in murine CD4 + cell subsets. J.  Exp.  Med.  178: 
1637-1644. 
37. Chu,  E.B.,  M.V.  Hobbs,  D.N.  Ernst,  and  W.O.  Weigle. 
1995.  In vivo  tolerance  induction and  associated  cytokine 
production by subsets of murine CD4 + T  cells. J.  lmmunol. 
154:4909-4914. 
38. Van Mechelen, M., D. De Wit, M. 1Kyelandt, S. Hjulstr6m, 
M. Heyndericlcx, H. Bazin, J. Urbain, and O. Leo.  1995. In- 
duction of Th2 responses to soluble proteins is independent 
of B cell tolerance status. Int. Immunol. 7:199-205. 
39. Burstein, H.J.,  and A.K. Abbas.  1993. In vivo role  of inter- 
leukin 4 in T cell tolerance induced by aqueous protein anti- 
gen.J. Exp.  Med. 177:457-463. 
40. Gajewski,  T.F., and F.W. Fitch.  1988. Anti-proliferative ef- 
fect of IFN-gamma in immune regulation. I. IFN-gamma in- 
hibits the proliferation of Th2 but not Thl murine helper T 
lymphocyte clones. J. Immunol. 140:4245-4253. 
41. Bradley, L.M., D.D. Duncan, S. Tonkonogy, and S.L. Swain. 
1991.  Characterization of antigen-specific  CD4 + effector  T 
cells in vivo: immunization results in a transient population 
ofMel-14-, CD45RB  helper T  cells that secretes interleu- 
kin-2 (IL-2), IL-3,  IL-4, and interferon-',/.J. Exp.  Med.  174: 
547-559. 
42. Gollob, K.J., and P,.L. Coffman. 1994. A minority subpopu- 
lation of CD4 +  T  cells directs  the  development of naive 
CD4 + T cells into IL-4-secreting cells.J.  Immunol. 152:518{i)- 
5188. 
43. Macatonia, S.E.,  N.A.  Hosken, M.  Litton, P.  Vieira,  C.-S. 
Hsieh,  J.A.  Culpepper,  M.  Wysocka,  G.  Trinchieri, K.M. 
Murphy,  and  A.  O'Garra.  1995. Dendritic  cells produce 
IL-12 and direct  the  development of Thl  cells from naive 
CD4 + T cells._/. Immunol. 154:5071-5079. 
44. Day,  MJ.,  A.G.D.  Tse,  M.  Puklavec,  S.J. Simmonds, and 
D.W. Mason.  1992. Targeting autoantigen to B cells prevents 
the induction of a cell-mediated autoimmune disease in rats. 
J. Exp. Med. 175:655-659. 
45. Saoudi,  A.,  S.  Simmonds,  I.  Huitinga, and  D.W.  Mason. 
1995. Prevention of experimental allergic encephalomyelitis 
in rats by targeting autoantigen to B cells: evidence that  the 
protective mechanism depends on changes  in the  cytokine 
response  and migratory properties  of autoantigen-specific T 
cells.J.  Exp.  Med. 182:335-344. 
46. Eynon, E.E.,  and D.C. Parker.  1993. Parameters of tolerance 
induction by antigen targeted  to B lymphocytes. J.  bnmunol. 
151:2958-2964. 
47. Scott, B., R. Liblau, S. Degermann, L.A. Marconi, L. Ogata, 
A.J. Caton,  H.O.  McDevitt,  and D.  Lo.  1994. A  role for 
496  Inhibition  of Thl and Priming of Th2 Cells by Soluble Antigen non-MHC genetic polymorphism in susceptibility to sponta- 
neous autoimmunity. Immunity.  1:1-20. 
48. Szabo, SJ., N.G. Jacobson, A.S. Dighe, U. Gubler, and K.M. 
Murphy. 1995.  Developmental commitment to the Th2 lin- 
eage by extinction oflL-12 signaling. Immunity. 2:665-675. 
49. Miller, A.,  O.  Lider, A.B.  Roberts, M.B.  Sporn,  and H.L. 
Weiner. 1992.  Suppressor T  cells generated by oral toleriza- 
tion to myelin basic protein suppress both in vitro and in vivo 
immune responses by the release of transforming growth fac- 
tor beta after antigen-specific triggering. Pro& Natl. Acad. Sci. 
USA. 89:421-425. 
50.  O'Garra, A., and K. Murphy. 1994.  Role of cytokines in de- 
termining T-lymphocyte function.  Curr. Opin.  Immunol. 6: 
458-466. 
51.  Sher, A., R.T. Gazzinelli, I.P. Oswald, M. Clerici, M. Kull- 
berg, EJ. Pearce, J.A. Berzofsky, T.R. Mosmann, S.L. James, 
and H.C. Morse.  1992.  Role of T-cell derived cytokines in 
the downregulation of immune responses in parasitic and ret- 
roviral infection. ImmunoI. Rev. 127:183-204. 
497  Gu6ry et al. 